Abstracts tagged "Prognostic factors and rheumatoid arthritis (RA)"

Abstract Number: 1214 • 2012 ACR/ARHP Annual Meeting
The Impact of Periodontal Disease On Early Inflammatory Arthritis Persists Even After All Teeth Are Lost
Gisela Westhoff¹, Paola de Pablo², Thomas Dietrich³, Georg Schett⁴ and Angela Zink⁵, ¹Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany, ²Rheumatology, College of Medical & Dental Sciences, IBR 3rd floor, University of Birmingham, Birmingham, United Kingdom, ³College of Medical and Dental Sciences, The School of Dentistry, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Data suggests that individuals with periodontal disease (PD) may be more likely to develop rheumatoid arthritis (RA) and have worse disease activity. PD is…
Abstract Number: 830 • 2012 ACR/ARHP Annual Meeting
Five-Year Favourable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data From the Espoir Cohort
Bernard G. Combe¹, Nathalie Rincheval², Joelle Benessiano³, Francis Berenbaum⁴, Alain G. Cantagrel⁵, Jean-Pierre Daurès², Maxime Dougados⁶, Patrice Fardellone⁷, Bruno Fautrel⁸, Rene-Marc Flipo⁹, Philippe M. Goupille¹⁰, Francis Guillemin¹¹, Xavier X. Le Loet¹², Isabelle Logeart¹³, Xavier Mariette¹⁴, Olivier Meyer¹⁵, Philippe Ravaud¹⁶, Alain Saraux¹⁷, Thierry Schaeverbeke¹⁸ and Jean Sibilia¹⁹, ¹Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Institut Universitaire de Recherche Clinique, Montpellier, France, ³Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, ⁴Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ⁵Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Service de Rhumatologie, C.H.U. D'Amiens, Amiens, France, ⁸Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹⁰Rheumatology, Hopital Trousseau, Tours, France, ¹¹Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, ¹²Rheumatology Department, CHU de ROUEN, Rouen, France, ¹³Pfizer, Paris, France, ¹⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁵Rheumatology, Hopital Bichat, Paris, France, ¹⁶Rheumatology Department, Hotel Dieu University hospital, Paris, France, ¹⁷Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁸Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁹Rhumatologie, CHU Hautepierre, Strasbourg, France
Background/Purpose: To report the five-year outcome of a large national multicentre, longitudinal and prospective cohort of patients with very early arthritis and rheumatoid arthritis (RA)…
Abstract Number: 363 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Pernille Bøyesen², Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Ditte Dencker¹, Hanne M. Lindegaard³, Uta Engling Poulsen¹, Annette Hansen⁴, Vibeke Stevenius Ringsdal¹, Annette Schlemmer⁵, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Torben Grube Christensen¹, Randi Pelck¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹, Ole Majgaard¹ and Merete L. Hetland⁶, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ³Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁴Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: : Despite treatment with tumour necrosis factor inhibitors (TNFi) some rheumatoid arthritis (RA) patients progress radiographically in randomised controlled trials and observational cohorts (1).…
Abstract Number: 2522 • 2012 ACR/ARHP Annual Meeting
M-Ficolin, an Activator of the Complement System, Is the Strongest Predictor of Both DAS28 Remission and Low Disease Activity in a Cohort of 180 Early DMARD Naïve Rheumatoid Arthritis Patients Followed in the Opera-Study
Christian G. Ammitzbøll¹, Jens Christian Jensenius², Torkell Ellingsen³, Steffen Thiel², Kim Hørslev-Petersen⁴, Merete L. Hetland⁵, Peter Junker⁶, Julia Johansen⁷, Mikkel Østergaard⁸, Jan Pødenphant⁹ and Kristian Stengaard-Pedersen¹, ¹Arhus University Hospital, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark, ³Silkeborg Regional Hospital, Silkeborg, Denmark, ⁴Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁶Odense University Hospital, Odense, Denmark, ⁷Glostrup Hospital, Glostrup, Denmark, ⁸Copenhagen University Hospital Glostrup, Glostrup, Denmark, ⁹Gentofte Hospital
Background/Purpose: M-ficolin is a soluble pattern recognition molecule that activates the complement system. We recently reported a factor 300 difference in the synovial fluid M-ficolin…
Abstract Number: 2128 • 2012 ACR/ARHP Annual Meeting
Matrix Metalloproteinase 3: A Biomarker of Disease Activity in Rheumatoid Arthritis
Sandra Reuter¹, Torsten Matthias² and Bruno Larida³, ¹AIRA e.V., AESKU.KIPP Institute, Wendelsheim, Germany, ²AESKU.Diagnostics GmbH & Co. KG, Wendelsheim, Germany, ³AESKU.DIAGNOSTICS INC, Oakland, CA
Background/Purpose: New biomarkers for monitoring Rheumatoid Arthritis (RA) disease activity and prognosis of progression are urgently needed to individually optimize drug therapy and prevent joint…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].